◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BWAY

Brainsway Ltd (BWAY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-30

Brainsway Ltd (BWAY) operates in the MEDICAL DEVICES industry and is headquartered in Jerusalem, Israel with about 129 employees. Its market capitalization is roughly $449 million. In the fiscal year ended 2025-12-31, BWAY reported $52M in revenue and $8M in net income.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Interactive charts & full statements → Open the BWAY valuation workbench →

BWAY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2000-12-31
Total Revenue	$62M	$52M	$41M	$32M	$27M	$30M	$22M	$23M	$16M	$11M	$12M	$7M	$3M	$1M	$0M	$102M
Gross Profit	$46M	$39M	$31M	$23M	$20M	$23M	$17M	$18M	$13M	$9M	$9M	$5M	$3M	$1M	$0M	$44M
Gross Margin %	74.2%	75.4%	74.6%	73.9%	73.8%	77.8%	77.1%	77.8%	78.1%	76.7%	78.9%	78.4%	80.6%	83.3%	87.4%	42.8%
Operating Income (EBIT)	$7M	$4M	$1M	($5M)	($13M)	($5M)	($5M)	($8M)	($5M)	($7M)	($2M)	($5M)	($7M)	($4M)	($6M)	—
Operating Margin %	11.3%	8.3%	3.4%	-15.6%	-46.7%	-16.9%	-21.9%	-36.7%	-31.2%	-59.3%	-17.9%	-66.2%	-215.3%	-358.9%	-1560.2%	—
Net Income	$10M	$8M	$3M	($4M)	($13M)	($6M)	($5M)	($10M)	($6M)	($7M)	($2M)	($4M)	($7M)	($7M)	($6M)	—
Net Margin %	16.1%	14.6%	7.1%	-13.2%	-49.1%	-21.8%	-24.4%	-44.7%	-39.5%	-63.3%	-20.8%	-60.1%	-193.6%	-599.0%	-1624.3%	—
EBITDA	$12M	$11M	$5M	($3M)	($11M)	($5M)	($2M)	($7M)	($4M)	($6M)	($1M)	($3M)	($6M)	($4M)	($6M)	—
Earnings Per Share (EPS)	$0.22	$0.18	$0.04	$-0.07	$-0.20	$-0.10	$-0.12	$-0.51	$-0.20	$-0.48	$-0.09	$-0.14	$-0.23	$-0.28	$-0.24	—
Shares Outstanding (M)	40M	42M	70M	66M	66M	62M	44M	20M	34M	14M	30M	28M	28M	26M	24M	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BWAY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$17M	$16M	$15M	$14M	$13M	$12M	$11M	$11M
Gross Profit	$13M	$12M	$11M	$10M	$9M	$9M	$9M	$8M
Gross Margin %	74.6%	75.2%	76.4%	75.2%	75.2%	74.6%	74.6%	73.5%
Operating Income (EBIT)	$2M	$2M	$2M	$1M	$1M	$1M	$0M	$0M
Operating Margin %	14.0%	12.9%	13.2%	9.3%	4.6%	5.0%	3.8%	2.7%
Net Income	$3M	$2M	$3M	$2M	$2M	$1M	$2M	$1M
Net Margin %	15.8%	14.7%	20.2%	11.6%	16.1%	9.6%	13.6%	6.3%
EBITDA	$3M	$3M	$3M	$3M	$3M	$2M	$1M	$2M
Earnings Per Share (EPS)	$0.07	$0.06	$0.07	$0.02	$0.03	$0.01	$0.02	$0.01
Shares Outstanding (M)	40M	38M	42M	76M	76M	74M	78M	66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BWAY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2000-12-31
Cash from Operations (CFO)	$7M	$18M	$10M	$1M	($10M)	$1M	($1M)	($7M)	($4M)	($3M)	($2M)	($5M)	($4M)	($2M)	($6M)	—
Capital Expenditures (CapEx)	$4M	$2M	$4M	$2M	$10M	$2M	$2M	$3M	$2M	$1M	$0M	$2M	$1M	$4M	$0M	$36M
Free Cash Flow (FCF)	$4M	$16M	$7M	($1M)	($19M)	($1M)	($4M)	($11M)	($6M)	($4M)	($3M)	($7M)	($5M)	($6M)	($6M)	—
FCF Margin %	6.5%	31.4%	15.9%	-3.5%	-71.7%	-4.6%	-17.7%	-45.7%	-35.0%	-40.0%	-24.4%	-100.3%	-156.5%	-538.9%	-1628.5%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BWAY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$6M	$1M	($1M)	$1M	$12M	$5M	$3M	$2M
Capital Expenditures (CapEx)	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Free Cash Flow (FCF)	$5M	$0M	($2M)	$1M	$11M	$4M	$3M	$1M
FCF Margin %	31.4%	2.6%	-14.0%	4.3%	88.8%	34.4%	22.6%	9.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BWAY Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2000-12-31
Total Assets	$122M	$113M	$94M	$63M	$64M	$76M	$34M	$39M	$24M	$27M	$20M	$22M	$26M	$18M	$11M	$77M
Cash & Cash Equivalents	$62M	$68M	$69M	$11M	$48M	$17M	$17M	$22M	$9M	$15M	$9M	$11M	$17M	$11M	$3M	$5M
Total Liabilities	$43M	$40M	$32M	$21M	$19M	$18M	$14M	$15M	$17M	$14M	$10M	$9M	$10M	$3M	$3M	$35M
Total Debt (Short + Long-Term)	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$3M	$4M	$1M	$0M	$0M	$0M	$0M	$4M
Total Shareholders' Equity	$79M	$73M	$62M	$42M	$45M	$57M	$20M	$24M	$7M	$13M	$10M	$13M	$16M	$8M	$5M	$42M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BWAY viewer.

Other Companies in MEDICAL DEVICES

SENS · Senseonics Holdings, Inc. Common Stock — $503 million
DCTH · Delcath Systems Inc — $500 million
CERS · Cerus Corporation — $472 million
SSII · SS Innovations International Inc. Common Stock — $467 million
NPCE · Neuropace Inc — $422 million
OFIX · Orthofix Medical Inc — $369 million
CLPT · Clearpoint Neuro Inc — $342 million
PHG · Koninklijke Philips NV ADR — $28 billion

This page in other languages: עברית

← BWA All “B” companies BWB →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.